Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems

IF 5.4 2区 工程技术 Q1 BIOCHEMICAL RESEARCH METHODS
Lab on a Chip Pub Date : 2025-06-04 DOI:10.1039/D5LC00062A
David J. Bozym, David X. Zheng, Or-Yam Revach, Amir Aref and Russell W. Jenkins
{"title":"Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems","authors":"David J. Bozym, David X. Zheng, Or-Yam Revach, Amir Aref and Russell W. Jenkins","doi":"10.1039/D5LC00062A","DOIUrl":null,"url":null,"abstract":"<p >Preclinical <em>ex vivo</em> models capable of probing patient-specific tumor–immune interactions are particularly attractive candidates for interrogating mechanisms of resistance, developing predictors of response as well as assessing next-generation immunotherapeutics. By maintaining features of a patient's own tumor microenvironment, such patient-derived <em>ex vivo</em> models are poised to meaningfully contribute to the functional assessment of individual tumors to provide a tailored approach to treatment. Among contemporary <em>ex vivo</em> models, patient-derived organotypic tumor spheroids (PDOTS) have emerged as a promising microfluidic-based platform that is well positioned to become a useful tool for precision medicine efforts. The advantages and limitations of PDOTS and related state-of-the-art patient-derived tumor models, as well as ongoing challenges facing the clinical implementation of patient-derived <em>ex vivo</em> tumor models, are reviewed.</p>","PeriodicalId":85,"journal":{"name":"Lab on a Chip","volume":" 13","pages":" 3038-3059"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lab on a Chip","FirstCategoryId":"5","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/lc/d5lc00062a","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Preclinical ex vivo models capable of probing patient-specific tumor–immune interactions are particularly attractive candidates for interrogating mechanisms of resistance, developing predictors of response as well as assessing next-generation immunotherapeutics. By maintaining features of a patient's own tumor microenvironment, such patient-derived ex vivo models are poised to meaningfully contribute to the functional assessment of individual tumors to provide a tailored approach to treatment. Among contemporary ex vivo models, patient-derived organotypic tumor spheroids (PDOTS) have emerged as a promising microfluidic-based platform that is well positioned to become a useful tool for precision medicine efforts. The advantages and limitations of PDOTS and related state-of-the-art patient-derived tumor models, as well as ongoing challenges facing the clinical implementation of patient-derived ex vivo tumor models, are reviewed.

Abstract Image

患者来源的器官型球形肿瘤、类肿瘤和类器官:利用最先进的3D肿瘤模型系统推进免疫治疗
能够探测患者特异性肿瘤-免疫相互作用的临床前离体模型是询问耐药机制,开发反应预测因子以及评估下一代免疫治疗方法的特别有吸引力的候选者。通过保持患者自身肿瘤微环境的特征,这种患者衍生的离体模型有望为个体肿瘤的功能评估做出有意义的贡献,从而提供量身定制的治疗方法。在当代离体模型中,患者来源的器官型肿瘤球体(PDOTS)已经成为一种有前途的基于微流体的平台,它很好地定位于成为精准医学工作的有用工具。本文综述了PDOTS及其相关的最新患者源性肿瘤模型的优点和局限性,以及临床实施患者源性体外肿瘤模型所面临的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lab on a Chip
Lab on a Chip 工程技术-化学综合
CiteScore
11.10
自引率
8.20%
发文量
434
审稿时长
2.6 months
期刊介绍: Lab on a Chip is the premiere journal that publishes cutting-edge research in the field of miniaturization. By their very nature, microfluidic/nanofluidic/miniaturized systems are at the intersection of disciplines, spanning fundamental research to high-end application, which is reflected by the broad readership of the journal. Lab on a Chip publishes two types of papers on original research: full-length research papers and communications. Papers should demonstrate innovations, which can come from technical advancements or applications addressing pressing needs in globally important areas. The journal also publishes Comments, Reviews, and Perspectives.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信